Rivaroxaban approved for use in EU (and UK) for treatment, and prevention of recurrence of venous thromboembolism

It will be licensed for treatment and prevention of venous thromboembolism recurrence in children from birth to below 18 years old, at least five days after initial parenteral anticoagulation treatment.

PharmaTimes